MAM
TOVX icon

Meeder Asset Management’s Theriva Biologics TOVX Stock Holding History

Meeder Asset Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10
Closed -$7K – 1801
2018
Q3 		$7K Buy
10
+9
+900% +$9.95K ﹤0.01% 1258
2018
Q2 		$1.36K Hold
1
– – ﹤0.01% 1458
2018
Q1 		$2K Hold
1
– – ﹤0.01% 1398
2017
Q4 		$3K Hold
1
– – ﹤0.01% 1444
2017
Q3 		$5K Hold
1
– – ﹤0.01% 1282
2017
Q2 		$4K Hold
1
– – ﹤0.01% 1273
2017
Q1 		$5K Sell
1
-1
-50% -$6.98K ﹤0.01% 1096
2016
Q4 		$10K Buy
+2
New +$20.5K ﹤0.01% 759

Other funds holding TOVX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Meeder Asset Management's TOVX Position: Q4 2018 in Review

Meeder Asset Management sold out of Theriva Biologics (TOVX) in Q4 2018, closing a stake of 10 shares — an estimated $7K sold.

Meeder Asset Management first reported a position in TOVX in Q4 2016 and held it in 8 quarters. The position peaked at $10K in Q4 2016. 23 funds tracked by Wall St. Rank hold TOVX as of Q4 2018.

  • Meeder Asset Management reported no remaining Theriva Biologics position as of Q4 2018 after selling out during the quarter.
  • Meeder Asset Management sold 10 Theriva Biologics shares in Q4 2018, an estimated $7K.
  • Meeder Asset Management first reported a position in Theriva Biologics in Q4 2016 and held it in 8 quarters.
  • Meeder Asset Management's Theriva Biologics position peaked at $10K in Q4 2016.
  • 23 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2018.

Based on Meeder Asset Management's 13F filing for Q4 2018, filed 17 Jan 2019.